Soligenix Inc (SNGX)
0.4006
-0.01
(-1.43%)
USD |
NASDAQ |
May 07, 16:00
0.4006
0.00 (0.00%)
After-Hours: 19:16
Soligenix Enterprise Value: -0.9081M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 06, 2024 | -0.9081M |
May 03, 2024 | -0.9281M |
May 02, 2024 | -0.9281M |
May 01, 2024 | -1.018M |
April 30, 2024 | -1.081M |
April 29, 2024 | -0.8281M |
April 26, 2024 | -0.8176M |
April 25, 2024 | -0.6913M |
April 24, 2024 | -1.154M |
April 23, 2024 | -0.9755M |
April 22, 2024 | -0.9144M |
April 19, 2024 | -0.6492M |
April 18, 2024 | -0.604M |
April 17, 2024 | 0.1822M |
April 16, 2024 | -0.2177M |
April 15, 2024 | -0.2388M |
April 12, 2024 | -1.122M |
April 11, 2024 | -1.094M |
April 10, 2024 | -0.3124M |
April 09, 2024 | -0.2903M |
April 08, 2024 | -0.0862M |
April 05, 2024 | -0.223M |
April 04, 2024 | -0.2377M |
April 03, 2024 | -0.0788M |
April 02, 2024 | 0.498M |
Date | Value |
---|---|
April 01, 2024 | 0.7084M |
March 28, 2024 | 1.129M |
March 27, 2024 | 1.204M |
March 26, 2024 | 1.024M |
March 25, 2024 | 1.340M |
March 22, 2024 | 1.496M |
March 21, 2024 | 1.550M |
March 20, 2024 | 1.396M |
March 19, 2024 | 1.350M |
March 18, 2024 | 1.235M |
March 15, 2024 | 1.340M |
March 14, 2024 | 1.517M |
March 13, 2024 | 2.243M |
March 12, 2024 | 2.287M |
March 11, 2024 | 2.567M |
March 08, 2024 | 2.885M |
March 07, 2024 | 3.129M |
March 06, 2024 | 3.068M |
March 05, 2024 | 3.441M |
March 04, 2024 | 3.234M |
March 01, 2024 | 2.876M |
February 29, 2024 | 2.487M |
February 28, 2024 | 2.313M |
February 27, 2024 | 2.498M |
February 26, 2024 | 2.287M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-6.008M
Minimum
Sep 01 2023
71.15M
Maximum
Dec 17 2020
20.14M
Average
16.75M
Median
Aug 16 2021
Enterprise Value Benchmarks
Eagle Pharmaceuticals Inc | -- |
Marinus Pharmaceuticals Inc | 3.984M |
NovaBay Pharmaceuticals Inc | 2.696M |
Palatin Technologies Inc | 22.79M |
iBio Inc | 16.80M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -1.820M |
Total Expenses (Quarterly) | 2.132M |
EPS Diluted (Quarterly) | -0.16 |
Earnings Yield | -224.7% |
Normalized Earnings Yield | -1195.33 |